Responsiveness of magnetic resonance imaging and neuropsychological assessment in memory clinic patients

Journal of Alzheimer's Disease

Volumn 40, Issue 2, 2014, Pages 409-418

  Schmand, Ben ^a,b   Rienstra, Anne ^b   Tamminga, Hyke ^b   Richard, Edo ^a   Van Gool, Willem A ^a   Caan, Matthan W A ^a   Majoie, Charles B ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Alzheimer's disease; cognition; hippocampus; longitudinal design; magnetic resonance imaging; mild cognitive impairment; neuropsychological tests; responsiveness

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN ATROPHY; BRAIN CORTEX; CLINICAL DEMENTIA RATING; COGNITION; COMPUTER PROGRAM; DEMOGRAPHY; DISEASE COURSE; EXECUTIVE FUNCTION; FEMALE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; NEUROLOGIST; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSYCHOMETRY; SAMPLE SIZE; SCORING SYSTEM; VERBAL COMMUNICATION; VERY ELDERLY; ALZHEIMER DISEASE; BRAIN; COMPLICATION; FOLLOW UP; MEMORY DISORDERS; MENTAL HEALTH; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY DISORDERS; MENTAL STATUS SCHEDULE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS;

EID: 84901924000     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131484     Document Type: Article

References (53)

1. Guyatt G, Walter S, Norman G (1987) Measuring change over time: Assessing the usefulness of evaluative instruments. J Chronic Dis 40, 171-178. (Pubitemid 17007065)
2. Revicki D, Hays RD, Cella D, Sloan J (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61, 102-109.
3. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141, 1356-1364.
4. Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412-2414. (Pubitemid 23346995)
5. Cummings J, Gould H, Zhong K (2012) Advances in designs for Alzheimer's disease clinical trials.AmJ Neurodegener Dis 1, 205-216.
6. Isaac M, Vamvakas S, Abadie E, Jonsson B, Gispen C, Pani L (2011) Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: Cerebrospinal- fluid related biomarkers for drugs affecting amyloid burden - Regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials. Eur Neuropsychopharmacol 21, 781-788.
7. Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G, European Task Force, Group (2008) Endpoints for trials in Alzheimer's disease: A European task force consensus. Lancet Neurol 7, 436-450. (Pubitemid 351509424)
8. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189- 198.
9. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R (1986) CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149, 698-709. (Pubitemid 17205276)
10. Zamrini E, De Santi S, TolarM(2004) Imaging is superior to cognitive testing for early diagnosis of Alzheimer's disease. Neurobiol Aging 25, 685-691. (Pubitemid 38686492)
11. de Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Tsui W, Saint Louis LA, Sobanska L, Brys M, Li Y, Rich K, Rinne J, Rusinek H (2007) Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci 1097, 114-145. (Pubitemid 47084889)
12. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M (2007) A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 64, 1323- 1329. (Pubitemid 47403089)
13. Monsell SE, Liu D,Weintraub S, KukullWA (2012) Comparing measures of decline to dementia in amnestic MCI subjects in the National Alzheimer's Coordinating Center (NACC) Uniform Data Set. Int Psychogeriatr 24, 1553-1560.
14. Schneider LS, Sano M (2009) Current Alzheimer's disease clinical trials: Methods and placebo outcomes. Alzheimers Dement 5, 388-397.
15. Coley N, Andrieu S, Jaros M,Weiner M, Cedarbaum J, Vellas B (2011) Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials. Alzheimers Dement 7, 602-610.e2.
16. Jack CR Jr, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, XuY, Shiung M, O'Brien PC, Cha R, Knopman D, PetersenRC(2003)MRIas a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 60, 253-260. (Pubitemid 36152018)
17. Ard MC, Edland SD (2011) Power calculations for clinical trials in Alzheimer's disease. J Alzheimers Dis 26(Suppl 3), 369-377.
18. Grill JD, Di L, Lu PH, Lee C, Ringman J, Apostolova LG, Chow N, Kohannim O, Cummings JL, Thompson PM, Elashoff D, Alzheimer's Disease Neuroimaging Initiative (2013) Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. Neurobiol Aging 34, 62-72.
19. Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M,Winblad B, Coley N, Vellas B, Oxford Task Force Grp (2011) Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol 95, 579-593.
20. Shi F, Liu B, Zhou Y, Yu C, Jiang T (2009) Hippocampal volume and asymmetry in mild cognitive impairment and Alzheimer's disease: Meta-analyses of MRI studies. Hippocampus 19, 1055-1064.
21. Han L, Cole M, Bellavance F, McCusker J, Primeau F (2000) Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: A meta-analysis. Int Psychogeriatr 12, 231-247. (Pubitemid 30490970)
22. Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T, Alzheimer's Disease Working Group (2010) Disease progression meta-analysis model in Alzheimer's disease. Alzheimers Dement 6, 39-53.
23. Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE, Alzheimer's Disease Neuroimaging Initiative (2011) Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry 68, 961-969.
24. Velayudhan L, Proitsi P,Westman E, Muehlboeck JS, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, Spenger C, Hodges A, Powell J, Lovestone S, Simmons A, dNeuroMed Consortium (2013) Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease. J Alzheimers Dis 33, 755-766.
25. Wouters H, Appels B, van der FlierWM,van Campen J, Klein M, Zwinderman AH, Schmand B, van GoolWA, Scheltens P, Lindeboom R (2012) Improving the accuracy and precision of cognitive testing in mild dementia. J Int Neuropsychol Soc 18, 314-322.
26. Wouters H, van Gool WA, Schmand B, Lindeboom R (2008) Revising the ADAS-cog for a more accurate assessment of cognitive impairment. Alzheimer Dis Assoc Disord 22, 236- 244.
27. Riepe MW, Janetzky W, Lemming OM (2011) Measuring therapeutic efficacy in patients with Alzheimer's disease: role of instruments. Dement Geriatr Cogn Disord 31, 233-238.
28. Balsis S, Unger AA, Benge JF, Geraci L, Doody RS (2012) Gaining precision on the Alzheimer's Disease Assessment Scale-cognitive: A comparison of item response theory-based scores and total scores. Alzheimers Dement 8, 288-294.
29. Backman L, Jones S, Berger AK, Laukka EJ, Small BJ (2005) Cognitive impairment in preclinical Alzheimer's disease: A meta-analysis. Neuropsychology 19, 520-531. (Pubitemid 41077134)
30. Zakzanis KK (1998) Quantitative evidence for neuroanatomic and neuropsychological markers in dementia of the Alzheimer's type. J Clin Exp Neuropsychol 20, 259-269. (Pubitemid 28451705)
31. Clerx L, Visser PJ, Verhey F, Aalten P (2012) New MRI markers for Alzheimer's disease: A meta-analysis of diffusion tensor imaging and a comparison with medial temporal lobe measurements. J Alzheimers Dis 29, 405-429.
32. Schmand B, Huizenga HM, van Gool WA (2010) Metaanalysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease. Psychol Med 40, 135-145.
33. Rienstra A, Groot PF, Spaan PE, Majoie CB, Nederveen AJ, Walstra GJ, de Jonghe JF, van Gool WA, Olabarriaga SD, Korkhov VV, Schmand B (2013) Symptom validity testing in memory clinics: Hippocampal-memory associations and relevance for diagnosing mild cognitive impairment. J Clin Exp Neuropsychol 35, 59-70.
34. Lezak MD (2012) Neuropsychological Assessment. Oxford University Press, Oxford; New York.
35. Schmand B, Houx P, de Koning I (2012) Normen van psychologische tests voor gebruik in de klinische neuropsychologie, Nederlands Instituut van Psychologen, Utrecht. www.psynip.nl.
36. UNESCO (1997) International Standard Classification of Education. ISBN 92-9189-035-9.
37. Fischl B, Sereno MI, Dale AM (1999) Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage 9, 195-207. (Pubitemid 29369875)
38. Dale AM, Fischl B, Sereno MI (1999) Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 9, 179-194. (Pubitemid 29369874)
39. Reuter M, Schmansky NJ, Rosas HD, Fischl B (2012)Withinsubject template estimation for unbiased longitudinal image analysis. Neuroimage 61, 1402-1418.
40. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van derKouwe A, Killiany R,Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM (2002) Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron 33, 341-355. (Pubitemid 34162530)
41. Fischl B, Stevens AA, Rajendran N, Yeo BT, Greve DN, Van Leemput K, Polimeni JR, Kakunoori S, Buckner RL, Pacheco J, Salat DH, Melcher J, FroschMP, Hyman BT, Grant PE, Rosen BR, van der Kouwe AJ, Wiggins GC, Wald LL, Augustinack JC (2009) Predicting the location of entorhinal cortex from MRI. Neuroimage 47, 8-17.
42. Tae WS, Kim SS, Lee KU, Nam EC, Kim KW (2008) Validation of hippocampal volumes measured using a manual method and two automated methods (FreeSurfer and IBASPM) in chronic major depressive disorder. Neuroradiology 50, 569-581.
43. Lehmann M, Douiri A, Kim LG, Modat M, Chan D, Ourselin S, Barnes J, Fox NC (2010) Atrophy patterns in Alzheimer's disease and semantic dementia: A comparison of FreeSurfer and manual volumetric measurements. Neuroimage 49, 2264- 2274.
44. Morey RA, Petty CM, Xu Y, Hayes JP, Wagner HR, 2nd, Lewis DV, LaBar KS, Styner M, McCarthy G (2009) A comparison of automated segmentation and manual tracing for quantifying hippocampal and amygdala volumes. Neuroimage 45, 855-866.
45. Hua X, Gutman B, Boyle CP, Rajagopalan P, Leow AD, Yanovsky I, Kumar AR, Toga AW, Jack CR Jr, Schuff N, Alexander GE, Chen K, Reiman EM, Weiner MW, Thompson PM, Alzheimer's Disease Neuroimaging Initiative (2011) Accurate measurement of brain changes in longitudinal MRI scans using tensor-based morphometry. Neuroimage 57, 5-14.
46. Barnes J, Bartlett JW, van de Pol LA, Loy CT, Scahill RI, Frost C, Thompson P, Fox NC (2009) A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging 30, 1711-1723.
47. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B (2011) Report of the task force on designing clinical trials in early (predementia) AD. Neurology 76, 280-286.
48. Bossuyt PM, Reitsma JB, Standards for reporting of diagnostic, accuracy (2003) The STARD initiative. Lancet 361, 71.
49. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, QUADAS-2 Group (2011) QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155, 529-536.
50. Huizenga HM, Smeding H, Grasman RP, Schmand B (2007) Multivariate normative comparisons. Neuropsychologia 45, 2534-2542. (Pubitemid 46946880)
51. Zhou B, Teramukai S, Yoshimura K, Fukushima M (2009) Validity of cerebrospinal fluid biomarkers as endpoints in early-phase clinical trials for Alzheimer's disease. J Alzheimers Dis 18, 89-102.
52. Schmand B, Eikelenboom P, van Gool WA, Alzheimer's Disease Neuroimaging Initiative (2012) Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment. J Alzheimers Dis 29, 641-648.
53. Pater C (2011) Mild cognitive impairment (MCI) - the novel trend of targeting Alzheimer's disease in its early stages - methodological considerations. Curr Alzheimer Res 8, 798- 807.